Show simple item record

dc.contributor.authorMohr, E
dc.contributor.authorFerlazzo, G
dc.contributor.authorHewison, C
dc.contributor.authorDe Azevedo, V
dc.contributor.authorIsaakidis, P
dc.date.accessioned2019-06-05T15:41:56Z
dc.date.available2019-06-05T15:41:56Z
dc.date.issued2019-05-01
dc.date.submitted2019-05-01
dc.identifier.urihttp://hdl.handle.net/10144/619386
dc.description.abstractHere we report on the final outcomes for the cohort of 28 patients from Armenia, India, and South Africa who initiated regimens containing the combination of bedaquiline and delamanid from January to August, 2016, for the treatment of multidrug-resistant tuberculosis in our cohort study.1 The median duration on combination treatment was 12 months (interquartile range [IQR] 5·9–20·0); 17 (61%) of 28 patients received the combination for more than 6 months.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsWith thanks to Elsevier.en_US
dc.titleBedaquiline and delamanid in combination for treatment of drug-resistant tuberculosisen_US
dc.identifier.journalLancet Infectious Diseasesen_US
refterms.dateFOA2019-06-05T15:41:56Z


Files in this item

Thumbnail
Name:
Mohr et al - 2019 - Bedaquiline ...
Size:
41.40Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record